Neurocrine Biosciences, Inc.
This report considers whether a broader medicines portfolio can generate lasting cash growth per share after commercial spending and research costs.
What we found.
A leading franchise
Ingrezza supplied approximately 88% of 2025 sales, creating exposure to reimbursement changes and competing treatments.
A broader portfolio
Crenessity offers diversification, although the modeled $1.94 billion in 2030 sales requires substantial expansion.
Investment and execution
The Vykat XR acquisition and a larger development budget must deliver returns sufficient to justify their costs.
Read the full analysis.
The report’s base valuation was $188.54 at a 10% required return, compared with $156.22 on September 11, 2026. Less favorable Crenessity activity and higher recurring expenses reduced the estimate to $155.78.
This page summarizes research published September 14, 2026. Figures and valuations reflect that report’s assumptions and reference dates, and may not be updated. Valuation estimates are not price targets or predictions. Read the full report for the analysis, assumptions, and disclosures.